Close
Close
Treatment News

ReNeuron chief on orphan status for eye treatment

3.0
3.0 from 3 votes
Monday, September 02, 2013

Learn more about:

Access Programs

ReNeuron (LON:RENE) has received orphan drug designation for its stem cell treatment for the degenerative eye disease retinitis pigmentosa. Here chief executive Michael Hunt explains to Proactiveinvestors, what this means for the company and he discusses the positive impact its recent £33mln cash call has had on the share price.

Author: Jeremy Naylor
Source: Proactive Investors
3.0
3.0 from 3 votes
Free Newsletter
Related Videos
by Robert Derham
465 views